Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hepatic Arterial Infusion Chemotherapy Combine With Lenvatinib and PD-1 Inhibitors for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis.

NCT05166239 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT05166239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05166239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hepatic Arterial Infusion Chemotherapy Combine With Lenvatinib and PD-1 Inhibitors for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis.
Lead sponsor
Peking University
Phase
Phase 2
Overall status
Completed
Start date
January 10, 2022
Completion date
December 28, 2025
Enrollment
66 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, portal vein thrombosis